SLS•November 20, 2026 at 9:01 PM UTCPharmaceuticals, Biotechnology & Life Sciences

SELLAS Closes $172.5M Offering at $13, Realizing Dilution Risk but Extending Runway

Read source article

What happened

SELLAS closed an underwritten public offering of 13,269,231 shares at $13.00 per share, including full exercise of the underwriters' option, raising $172.5 million in gross proceeds before fees. This follows the August 2026 DeepValue report that flagged heavy dilution risk, with shares outstanding already up to 201.9 million from 153.1 million at year-end 2025, and an unused $150 million ATM still in place. The raise boosts pro forma cash from $138.3 million as of June 30, 2026 to roughly $300 million, removing near-term solvency pressure but increasing share count by approximately 6.6%. Management chose to raise at $13.00, a price near the upper end of the report's trim range of $13.50, suggesting opportunism rather than distress, but also signaling that insiders see limited near-term upside without new clinical data. Critically, the capital injection does not alter the core dependency on the REGAL Phase 3 readout, which remains event-driven, blinded, and unresolved as of the last disclosure.

Implication

The offering materializes the dilution risk previously identified, reducing per-share upside even if REGAL succeeds, while extending cash runway well beyond twelve months and eliminating bankruptcy risk. The $13.00 pricing suggests management views the stock as fully valued, aligning with the prior report's potential sell rating and trim guidance above $13.50. Investors should now focus on the next catalysts—official 80th-event announcement, topline data, and SLS009 enrollment progress—as these will determine whether the expanded share base can still generate attractive returns. For existing holders, the prudent move is to trim into strength above $13.50 or wait for a pullback toward the $8.00 attractive entry, while new investors should avoid chasing the offering pop given the unchanged binary risk. Overall, the dilution event does not improve the risk-reward, and the stock remains a speculative hold requiring lower exposure until clinical data de-risks the thesis.

Thesis delta

The dilution risk highlighted in the prior report has now materialized in the form of a $172.5 million offering at $13.00, increasing shares outstanding and directly reducing per-share value for existing holders. However, the company secured capital at a price above the report's base case of $10.00, which extends the cash runway and reduces balance-sheet risk, though it does not de-risk the binary REGAL outcome. The overall investment thesis remains unchanged: the stock still prices in a timely and positive Phase 3 readout, and the offering reinforces the potential sell rating, with slightly diminished downside from financing risk but increased dilution-adjusted downside if the data disappoints.

Confidence

medium